戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  13 of 63 tumors (35% of adenomas with overt Cushing's syndrome).
2 levoketoconazole in patients with endogenous Cushing's syndrome.
3  for the treatment of selected patients with Cushing's syndrome.
4 in a phase 2 clinical study in patients with Cushing's syndrome.
5 ons and reduce the mortality associated with Cushing's syndrome.
6 rapeutic option for the medical treatment of Cushing's syndrome.
7 nd treatment of endogenous hypercortisolism--Cushing's syndrome.
8 l focus on new diagnostics and treatments of Cushing's syndrome.
9 the fat distribution changes associated with Cushing's syndrome.
10 struction in multiple myeloma and endogenous Cushing's syndrome.
11 tumors autonomously producing cortisol cause Cushing's syndrome.
12 perplasia is a rare cause of primary adrenal Cushing's syndrome.
13  promising therapeutics for the treatment of Cushing's syndrome.
14 r it may be identified during evaluation for Cushing's syndrome.
15 YP11B1 inhibition is a promising therapy for Cushing's syndrome.
16 ring conditions of circulating excess, e.g., Cushing's syndrome.
17  has been implicated based on parallels with Cushing's syndrome.
18 s (ACA), and hyperplasia (ACH) involved with Cushing's syndrome.
19 one suppression test were done to screen for Cushing's syndrome.
20 viously in a clinical trial in patients with Cushing's syndrome.
21   Of the 94 patients, 80 (85%) had pituitary Cushing's syndrome.
22 producing adrenocortical adenomas leading to Cushing's syndrome.
23 n neoplasms contribute to the development of Cushing's syndrome.
24 naling caused by PRKACA mutations in adrenal Cushing's syndrome.
25 ctivity and biases AKAP association to drive Cushing's syndrome.
26 ailor-made pharmacotherapy for patients with Cushing's syndrome.
27 tic subunit of PKA in tumors associated with Cushing's syndrome, a kidney disorder leading to excessi
28 resonance imaging (MRI) to determine adrenal Cushing's syndrome (ACS) in adrenal incidentalomas (AI).
29 ss model, adrenal tissues from patients with Cushing's syndrome, adrenocortical cell lines, and perip
30 recruited adults (>=18 years) with confirmed Cushing's syndrome and a mean 24-h urinary free cortisol
31  levels and cortisol-related disorders (e.g. Cushing's syndrome and Addison's disease).
32 KA fusion protein were found to be linked to Cushing's syndrome and FL-HCC, respectively.
33 rise the drug therapies for various forms of Cushing's syndrome and focus on emerging drugs and drug
34 stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously
35                                   In humans, Cushing's syndrome and long-term prescription corticoste
36 aecal headspace in two mouse models of T2D - Cushing's syndrome and single Afmid knockout mice.
37 olaemic patients, both those with endogenous Cushing's syndrome and, much more frequently, those rece
38 s glucocorticoid use may develop features of Cushing's syndrome and, subsequently, glucocorticoid wit
39 cially if associated with bone metastases or Cushing's syndrome), and the extent of liver metastases
40  leptin resistance occurs in aging, obesity, Cushing's syndrome, and acquired lipodystrophy, and prel
41 ur patients (diagnosed with Conn's syndrome, Cushing's syndrome, and Pheochromocytoma) who underwent
42 l gland disorders including Conn's syndrome, Cushing's syndrome, and Pheochromocytoma.
43 ong patients diagnosed with Conn's syndrome, Cushing's syndrome, and Pheochromocytoma.
44 n patients with macronodular hyperplasia and Cushing's syndrome appears to be regulated by corticotro
45 coids, such as major depressive disorder and Cushing's syndrome, are reported to have smaller hippoca
46            They die before 9 weeks of severe Cushing's syndrome arising from pituitary intermediate l
47 type 2 diabetes, and dyslipidemia) resembles Cushing's Syndrome, but without elevated circulating glu
48                                              Cushing's syndrome can be a challenging diagnosis to con
49                                              Cushing's syndrome (CS) is an abnormal condition charact
50 euroendocrine or metabolic disorders such as Cushing's syndrome (CS).
51 ary aldosteronism (PA) and hypercortisolism [Cushing's syndrome (CS)] in humans, we sequenced these 2
52 g methods were able to classify the recorded Cushing's syndrome diagnoses, with good predictive perfo
53                                       In the Cushing's syndrome disorder, we find that the L205R muta
54 hip suggests a possible common mechanism for Cushing's syndrome driving mutations in which decreased
55 hyperexcitability of the HPA axis, including Cushing's syndrome, epilepsy, and major depression.
56 one concentration, and a pituitary source of Cushing's syndrome, from 57 sites across 19 countries.
57                Hypertension in patients with Cushing's syndrome has a multifactorial pathogenesis and
58 erations associated with different causes of Cushing's syndrome have been described in the last decad
59 th CAH, and adults can experience iatrogenic Cushing's syndrome, hyperandrogenism, infertility, or th
60 king and contribute to improved diagnosis of Cushing's syndrome in dogs.
61 ticoids results in diverse manifestations of Cushing's syndrome, including debilitating morbidities a
62                                      Adrenal Cushing's syndrome is a disease of cortisol hypersecreti
63                                              Cushing's syndrome is a serious endocrine disease caused
64                                              Cushing's syndrome is an endocrine disease in dogs that
65                                              Cushing's syndrome is associated with multisystem morbid
66                    Corticotropin-independent Cushing's syndrome is caused by tumors or hyperplasia of
67                                   Endogenous Cushing's syndrome is caused either by excess ACTH secre
68                          Hypercortisolaemia (Cushing's syndrome) is characterised by abdominal fat ac
69                  High cortisol production in Cushing's syndrome leads to fat centralisation.
70 al development of bone metastases or ectopic Cushing's syndrome markedly decreased survival rate.
71 eric (L205R and W196R) and allosteric (E31V) Cushing's syndrome mutants, the loss of binding cooperat
72 , complications, and treatment of endogenous Cushing's syndrome of all causes.
73 of metastases; and the occurrence of ectopic Cushing's syndrome or another PET syndrome.
74 mph node, liver, or bone metastases; ectopic Cushing's syndrome; or higher gastrin levels.
75 owever, both the diagnosis and management of Cushing's syndrome remain challenging.
76                                   Endogenous Cushing's syndrome results from excess glucocorticoid se
77                                              Cushing's syndrome results from lengthy and inappropriat
78 nes, resulting from either drug treatment or Cushing's syndrome, results in insulin resistance, centr
79 eral adenomas (37%) from patients with overt Cushing's syndrome; these mutations were not detectable
80 h adenomas, and the dielectric properties of Cushing's syndrome tumour were lowest in comparison to t
81 ere applied to predict a future diagnosis of Cushing's syndrome, using structured clinical data from
82 t with symptoms of hormone excess, including Cushing's syndrome, virilization, feminization, or--less
83                     Dogs suspected of having Cushing's syndrome were included in the analysis and cla
84                            No other signs of Cushing's syndrome were observed, and plasma cortisol va
85    Age, weight, and diagnostic categories of Cushing's syndrome were similar between the two groups a
86 postoperative complications in patients with Cushing's syndrome who underwent bilateral adrenalectomy
87 ients undergoing bilateral adrenalectomy for Cushing's syndrome without other contraindications for u
88                                              Cushing's syndrome without virilization was uncommon (5.